Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055335 | 0.91 | TYMP (0.33) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17055317 | 0.90 | MAPT (0.33) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17055349 | 0.82 | CA1 (0.32) | — | |
| SCHEMBL17055341 | 0.81 | — | — | |
| SCHEMBL17055333 | 0.80 | CA1 (0.40) | — | |
| SCHEMBL2480097 | 0.79 | — | — | |
| SCHEMBL13616814 | 0.77 | LMNA (0.35) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL28412245 | 0.76 | — | — | |
| SCHEMBL871939 | 0.76 | — | — | |
| SCHEMBL28409399 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725590-B2 | Epoxy compound having alkoxysilyl group, method for preparing the same, composition including the same, cured product made from the composition, and use of the composition | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2017-08-08 | — | — | US | disclosed |
| US-20150247033-A1 | EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD FOR PREPARING THE SAME, COMPOSITION INCLUDING THE SAME, CURED PRODUCT MADE FROM THE COMPOSITION, AND USE OF THE COMPOSITION | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150247033-A1 | EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD FOR PREPARING THE SAME, COMPOSITION INCLUDING THE SAME, CURED PRODUCT MADE FROM THE COMPOSITION, AND USE OF THE COMPOSITION | ESD, ELL, ALOX5 | LMNA 444/4885CHRM2 4629/4885CHRM4 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.